Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The trial is planned as a multicentric, national, phase II, open-label trial to evaluate
safety and tolerance of nebulized Liposomal Amphotericin B (Ambisome) for LMA patients during
the induction therapy ,intensification, plus Allogeneic Haematopoietic Progenitor Cell
transplant in due course, as well for patients diagnosed of several malignant haematologic
diseases and treated with Allogeneic Haematopoietic Progenitor Cell Transplant